PYC Therapeutics Unveils Early Clinical Promise for RNA Therapies in Childhood Blindness

Emerging RNA Therapies Target Childhood Blindness

PYC Therapeutics (ASX:PYC) has spotlighted early clinical data from its pioneering RNA therapeutic candidates VP-001 and PYC-001, aimed at tackling two devastating genetic eye diseases of childhood: Retinitis Pigmentosa type 11 (RP11) and Autosomal Dominant Optic Atrophy (ADOA). Presented at the Association for Research in Vision and Ophthalmology (ARVO) conference in Denver, the data reveal promising safety profiles alongside encouraging efficacy signals in small patient cohorts.

Both drug candidates leverage PYC’s proprietary RNA-peptide conjugate platform designed to correct the underlying genetic defects causing progressive vision loss. VP-001 targets RP11 by upregulating PRPF31 gene expression, while PYC-001 focuses on increasing OPA1 protein levels in ADOA patients, addressing mitochondrial dysfunction that leads to retinal ganglion cell death.

PYC-001 Shows Safety and Visual Gains in ADOA

The SUNDEW Phase 1A single ascending dose study and ongoing MYRTLE multiple ascending dose trial of PYC-001 in genetically confirmed ADOA patients have demonstrated no treatment-related serious adverse events across doses up to 60 micrograms. Most adverse events were mild and procedure-related. Importantly, exploratory efficacy assessments showed improvements in low-contrast visual acuity in treated eyes compared to untreated fellow eyes, sustained over several months.

Preclinical studies in patient-derived retinal ganglion cell models and non-human primates support these clinical findings, with PYC-001 restoring mitochondrial structure and bioenergetic function. The 1.6-fold increase in OPA1 protein expression observed in primate retinas aligns with the drug’s mechanism of action and underscores its potential to modify disease progression in a mutation-agnostic manner.

These developments build on PYC’s recent progress, including the approval to escalate dosing in the MYRTLE study, reflecting a steady clinical advancement of PYC-001 through early-phase trials. The company’s focus on monogenic diseases with high genetic clarity positions PYC-001 as a leading candidate in the rare eye disease space. This momentum follows PYC’s significant capital infusion earlier in 2026 to fund pipeline expansion and clinical programs advancing PYC-001 to multiple dose.

VP-001 Data Reveal Meaningful Visual Improvements in RP11

VP-001, the first clinical-stage drug candidate for RP11, is being evaluated in multiple ongoing studies including the Phase 2 DINGO open-label extension. The drug aims to rescue haploinsufficiency of the PRPF31 gene, a critical splicing factor in retinal cells. Early data from Phase 1a and 1b studies (Platypus and Wallaby) showed VP-001 is safe and well tolerated, with no treatment-related serious adverse events reported.

Clinically meaningful improvements were observed in low-luminance visual acuity (LLVA) and retinal sensitivity measured by microperimetry, endpoints closely linked to patient quality of life. Notably, a higher proportion of VP-001 treated eyes achieved >10 letter gains in LLVA compared to untreated fellow eyes and natural history controls, suggesting a potential to slow or reverse vision loss in RP11 patients.

Patient testimonials reinforce these findings, with reports of clearer central vision and enhanced night-time sight, marking significant quality-of-life benefits. Long-term data from the ongoing Phase 2 study will inform the design of a registrational trial, targeting a 48-month treatment period with 90 patients randomized across dosing arms and sham controls. This regulatory pathway aligns with prior FDA discussions and recent positive regulatory milestones, including Orphan Drug Designation in Europe EMA Orphan Drug Status.

Advanced Imaging Corroborates Functional Benefits

Complementing clinical endpoints, advanced imaging techniques such as adaptive optics scanning light ophthalmoscopy, optoretinography, and microperimetry were employed to assess retinal structure and function before and after VP-001 treatment. These high-resolution modalities revealed maintenance or improvement in cone photoreceptor density and function in treated eyes, supporting the clinical efficacy signals.

Similarly, PYC-001’s mechanism was validated through detailed preclinical and clinical imaging, confirming its ability to upregulate OPA1 protein in retinal layers critical to vision. These sophisticated assessments provide mechanistic insights and objective measures that bolster the case for these RNA therapies as disease-modifying agents.

Next Steps in Clinical Development

PYC is advancing PYC-001 through the MYRTLE Phase 1b multiple ascending dose study to further establish safety and proof of concept, while VP-001 progresses through the DINGO Phase 2 extension with plans for a registrational trial. The company’s recent $600 million capital raise has fortified its financial position, enabling sustained development of these promising RNA therapies $600m capital boost.

While early data are encouraging, the small patient numbers and preliminary nature of efficacy signals warrant cautious optimism. Confirmation of clinical benefit in larger, controlled trials will be critical to validate these therapies’ potential to transform treatment options for patients with rare, currently untreatable childhood blinding diseases.